TSP802-CMap - carcinogenome project: Toxicogenomic signatures after exposure to methotrexate


TSA8584-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate


TSA9570-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to methotrexate


TSA9679-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to methotrexate


TSF8691-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 10.34 µM


1 subfactor(s)
TSF8690-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 20.68 µM


1 subfactor(s)
TSF8692-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 5.17 µM


1 subfactor(s)
TSF8693-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 2.59 µM


1 subfactor(s)
TSF8694-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 1.29 µM


1 subfactor(s)
TSF8695-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 0.65 µM


1 subfactor(s)
TSF12744-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to methotrexate 99.37 µM


1 subfactor(s)
TSF12745-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to methotrexate 33.12 µM


1 subfactor(s)
TSF12746-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to methotrexate 11.04 µM


1 subfactor(s)
TSF13077-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to methotrexate 99.37 µM


1 subfactor(s)
TSF13078-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to methotrexate 33.12 µM


1 subfactor(s)
TSF13079-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to methotrexate 11.04 µM


1 subfactor(s)
TSS8691-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 10.34 µM


TSS8690-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 20.68 µM


TSS8692-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 5.17 µM


TSS8693-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 2.59 µM


TSS8694-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 1.29 µM


TSS8695-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line HEPG2 after exposure to methotrexate 0.65 µM


TSS12745-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to methotrexate 99.37 µM


TSS12746-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to methotrexate 33.12 µM


TSS12747-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.TP53.M after exposure to methotrexate 11.04 µM


TSS13078-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to methotrexate 99.37 µM


TSS13079-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to methotrexate 33.12 µM


TSS13080-CMap - carcinogenome project: Toxicogenomic signatures in the human cell line MCF10A.WT.HP after exposure to methotrexate 11.04 µM



TSP802 - CMap - carcinogenome project: Toxicogenomic signatures after exposure to methotrexate Public


In the chemical selection process, we prioritized chemicals with long-term rodent liver carcinogenicity annotation for inclusion in this experiment. Long-term carcinogenicity annotations were derived from the Carcinogenic Potency Database (CPDB) (Fitzpatrick 2008). Additional chemicals without carcinogenicity annotation were included on the basis of interest to the Superfund Research Program (environmental toxicants), presence in controversial commercial products (included for predictive purposes), and evidence of binding to the aryl hydrocarbon receptor (AhR), as the AhR is an important mediator of xenobiotics, including carcinogens. In total, 330 unique chemicals were used in the analysis, including 128 carcinogens, 168 noncarcinogens, 100 genotoxicants, and 161 nongenotoxicants. (Li et al., 2019) Liver Carcinogenicitynon-carcinogen Liver Genotoxicitynon-genotoxic Breast Carcinogenicitynon-carcinogen Breast Genotoxicitynon-genotoxic

Experimental design


No experimental design provided

Results


No results provided